The government approves every drug, sets Medicare prices, and funds the research. Some of the lawmakers who do all three are also investors.
Pharmaceutical and biotech stocks are uniquely dependent on three government levers: FDA approval decisions, Medicare reimbursement rates, and drug pricing legislation. The congressional committees that control all three are legally permitted to hold positions in the companies they oversee.
$467B
in U.S. prescription drug spending in 2024, the majority of which flows through government programs at rates Congress ultimately controls
~50%
of all outpatient drug spending funded by federal and state government programs, with Medicare alone covering 32% of retail prescription sales
55
new drugs FDA approved in 2023, each a binary event capable of moving a biotech stock 30 to 60 percent in a single trading session
$200
the STOCK Act's maximum fine for a late disclosure, applied to members of the very committees that oversee drug pricing, FDA approvals, and Medicare reimbursements
Why pharmaceutical stocks are uniquely shaped by Washington
Every drug sold in the United States must be approved by the federal government. The price at which it is reimbursed for roughly half of all patients is set by the federal government. The foundational research behind 99.4% of drugs approved between 2010 and 2019, totaling $187 billion in public investment, was funded by the federal government through the NIH. No other sector has this depth of government dependency across the full value chain: research, approval, and payment.
This means that a small number of federal decisions, made by a small number of people, can move the stocks of pharmaceutical and biotech companies by magnitudes that are unmatched in any other industry. When the FDA approves a drug, a company's stock can rise 30 to 60 percent in a single trading session. When the FDA rejects an application with a Complete Response Letter, stocks can fall 50 to 80 percent overnight. When Congress passes drug pricing legislation that changes Medicare reimbursement rates, the revenue projections for some of the largest drugs in the world are rewritten in a single bill.
The STOCK Act of 2012 prohibits members of Congress from trading on material non-public information but does not ban ownership of stocks in sectors under their direct committee oversight. A senator on the HELP Committee, which writes FDA authorization legislation and receives classified briefings from agency leadership, can legally hold stock in the companies whose drug applications the FDA is reviewing. A member of the Senate Finance Committee, which wrote the Medicare drug price negotiation provisions of the Inflation Reduction Act and receives HHS implementation briefings, can legally hold stock in the companies whose drugs are being selected for negotiation. The enforcement gaps in that law mean the practical consequence for trading in this environment is a $200 fine for a late disclosure. No member of Congress has ever been criminally charged under the STOCK Act.
The structural result is a sector where the most consequential information, whether an FDA approval is likely, whether a specific drug will be selected for Medicare price negotiation, whether a drug pricing bill will pass in its current form or be amended, sits in the hands of a small group of legislators who are legally permitted to invest based on the same general knowledge their committee access provides.
The five committees that control pharmaceutical and biotech outcomes
Pharmaceutical and biotech stocks are shaped by two distinct government functions: drug approval (FDA authority) and payment policy (Medicare and Medicaid). These committees hold jurisdiction over both, and their members receive information unavailable to the market before it becomes public. See the full breakdown of how committee assignments create stock-trading conflicts across all sectors.
Senate HELP Committee (Health, Education, Labor and Pensions)
Primary FDA oversight, drug approval legislation, NIH funding authority
The HELP Committee has jurisdiction over the FDA and NIH, and it writes every major piece of FDA authorization legislation, including the reauthorizations of the Prescription Drug User Fee Act (PDUFA) that fund and govern the agency's drug review process. Members receive direct briefings from FDA leadership, attend closed-door hearings, and have access to information on drug review timelines and program-level trends that no outside investor does. The HELP Committee created the Breakthrough Therapy Designation in 2012 under FDASIA, a designation the FDA does not publicly disclose unless sponsors choose to announce it. HELP Committee members overseeing the FDA program receive aggregate data on these high-value designations across therapeutic areas. When a COVID-19 crisis briefing was convened in early 2020, it was through the HELP Committee that senators first received detailed government assessments of viral spread, treatment options, and the likely trajectory of an emergency health response. Those briefings preceded public disclosures by weeks.
Senate Finance Committee
Medicare, Medicaid, IRA drug pricing provisions, drug price negotiation methodology
The Finance Committee wrote the Medicare drug price negotiation provisions of the Inflation Reduction Act and has ongoing oversight of their implementation by CMS and HHS. This is the committee whose members understood the IRA's drug selection methodology before CMS formalized and published it publicly. The gap between when Finance Committee members understood which drugs would qualify for negotiation under the IRA's formula and when the August 29, 2023 announcement named the first 10 drugs represents a window during which an informed member could have anticipated the companies most exposed. Finance Committee members also receive HHS briefings on the trajectory of price negotiations, the companies resisting or cooperating with the negotiation process, and the expected savings projections, all of which directly affect the revenue outlook for some of the world's largest pharmaceutical companies.
House Energy and Commerce Committee
House FDA authority, Medicaid, 340B pricing program, drug safety oversight
The House counterpart to the HELP Committee for FDA jurisdiction, Energy and Commerce also has House sole jurisdiction over Medicaid and shares Medicare Parts B, C, and D authority with Ways and Means. This committee holds the drug pricing hearings, conducts CEO interrogations, and marks up House versions of FDA reauthorization bills. Its Health Subcommittee receives the same category of closed-door briefings as HELP. Rep. Michael Burgess held shares in vaccine manufacturers while sitting on the very subcommittee that questioned Pfizer and Moderna executives about their COVID vaccines. The committee's wide jurisdiction over the 340B drug discount program, which requires manufacturers to offer discounts to certain hospitals and clinics, adds another lever of government control over pharmaceutical revenue that committee members understand in advance of public announcements.
House Ways and Means Committee
Medicare Parts A and B payment policy, prescription drug program structure
The oldest committee in Congress (established 1789) controls the tax-financing of Medicare and sets payment rates for hospitals, physicians, and drugs under Medicare Parts A and B. The Health Subcommittee reviews the specific payment mechanisms that govern how much hospitals and providers are reimbursed for drugs administered in clinical settings, a category that encompasses many of the most expensive cancer therapies and biologics. Changes to the Part B drug reimbursement formula directly affect companies like Bristol-Myers Squibb, Merck, and Regeneron, whose oncology products are administered by physicians in hospital and outpatient settings. Members of Ways and Means who hold positions in these companies are invested in the payment structure they control.
Senate Select Committee on Intelligence
COVID-era pandemic intelligence, biological threat assessments, health crisis briefings
The Intelligence Committee is not a standard health oversight body, but in periods of health crisis its role becomes highly relevant to pharmaceutical investing. In early 2020, the Intelligence Committee was among the first bodies in Congress to receive classified assessments of the COVID-19 pandemic's likely spread, severity, and economic impact. The most documented congressional trading scandal of the modern era, centered on Senator Richard Burr's sales of up to $1.72 million in stocks one day after a HELP Committee briefing, occurred in a period when Burr simultaneously chaired the Intelligence Committee and served on the HELP Committee, giving him a uniquely broad view of both the classified threat assessment and the government's health response posture. The combination of these two committee assignments created an information position no ordinary investor could access.
Four moments when government decisions produced extraordinary pharma stock moves
These are specific government decisions that created information asymmetry between health committee members and ordinary investors. Each is documented. Each type will recur.
The COVID briefings and congressional sell-off (January to February 2020)
In early 2020, while the White House and public health officials were publicly downplaying the severity of COVID-19, congressional health and intelligence committees were receiving detailed classified briefings on the virus. The HELP Committee received multiple briefings from government health experts in late January and February 2020. On February 13, 2020, one day after attending a HELP Committee briefing, Senator Richard Burr of North Carolina sold between $628,000 and $1.72 million of stock through 33 separate transactions, representing approximately 95% of his personal retirement holdings. The following week he gave a private speech to a Washington social club describing the pandemic in far more alarming terms than any public statement he had made.
Senator Kelly Loeffler and her husband made 27 sell transactions worth between $1.275 million and $3.1 million following a January 24, 2020 classified Senate briefing. Senator David Perdue purchased Pfizer stock around the time he was publicly acknowledging attendance at coronavirus task force briefings. Rand Paul's wife Kelley purchased between $1,001 and $15,000 of Gilead Sciences stock on February 26, 2020, one day after Gilead's remdesivir began its first clinical trial as a COVID treatment. That purchase was disclosed 16 months late, in August 2021. All investigations were closed without charges.
The Biogen Alzheimer's approval: a 38 to 64 percent single-day gain (June 2021)
On June 7, 2021, the FDA granted accelerated approval to Biogen's Alzheimer's drug aducanumab (Aduhelm). Biogen stock surged between 38 and 64 percent in a single session, its largest single-day gain in years. The approval was one of the most controversial in the FDA's modern history: the agency's own advisory committee had voted 8 to 1 against the drug's efficacy in November 2020. The FDA overrode its expert panel and approved it anyway. Aduhelm was initially priced at $56,000 per year, later reduced to $28,200 under intense congressional scrutiny.
The episode illustrates the specific binary risk in pharma investing. Advisory committee votes are publicly scheduled but their substance is not pre-announced. FDA briefing documents are released only 2 to 3 days before an adcom meeting. The FDA overrides its own committees approximately 20% of the time in recent years. Members of the HELP Committee who oversee the FDA's Accelerated Approval pathway, which Biogen used, had access to congressional oversight briefings on the Alzheimer's drug review that went beyond what market participants could access from public filings. The CMS decision that followed, restricting Medicare coverage of Aduhelm to clinical trial participants, cut the drug's effective market dramatically and added another government-decision layer to the stock's trajectory.
The Inflation Reduction Act and the Medicare drug negotiation era (2022 to 2024)
The Inflation Reduction Act, signed August 16, 2022, gave the Secretary of HHS the authority to negotiate prices directly with pharmaceutical companies for high-expenditure Medicare drugs. This was the single largest change to pharmaceutical pricing law in two decades. Finance Committee members had spent months in closed-session markup debating which drugs would be covered, how the selection methodology would work, and which companies would face the largest revenue impact.
On August 29, 2023, CMS announced the first 10 drugs selected for negotiation. The list included Eliquis (Bristol-Myers Squibb and Pfizer), which had generated $16.4 billion in Medicare Part D spending in a single year, Xarelto (Johnson and Johnson), Januvia (Merck), Jardiance (Boehringer Ingelheim and Eli Lilly), Imbruvica (AbbVie), and Stelara (Johnson and Johnson). When final negotiated prices were announced in August 2024, the discounts ranged from 79% for Januvia (from $527 to $113 per month) to 38% for Imbruvica. Medicare is projected to save $6 billion annually from this first round alone. Finance and HELP Committee members who understood the selection methodology before August 2023 knew which companies faced the largest Medicare revenue exposure before the market did.
The GLP-1 era: FDA approvals and the weight loss drug revolution (2022 to 2024)
Eli Lilly's tirzepatide (Mounjaro for diabetes, Zepbound for obesity) became the defining drug regulatory story of the decade. Mounjaro received FDA approval for Type 2 diabetes on May 13, 2022. Zepbound received FDA approval for chronic weight management on November 8, 2023. Driven by these two approvals, Eli Lilly's stock rose 59% in 2023 alone, briefly making it the world's most valuable pharmaceutical company by market capitalization. Novo Nordisk's semaglutide (Ozempic for diabetes, Wegovy for obesity) followed a parallel trajectory, with Novo's profits rising 55% in 2023. The GLP-1 market was valued at approximately $52 billion in 2024 and is projected to reach $187 billion by 2032. HELP Committee members, through their oversight of the FDA approval process and their briefings on priority review timelines, had access to the framework within which these approvals were being evaluated. Separately, coverage and reimbursement decisions on GLP-1 drugs by CMS, which the Finance Committee oversees, will determine the market size for this category for the next decade. That determination is a multi-trillion-dollar question being answered in part by the same senators who are permitted to hold Lilly and Novo Nordisk stock.
Health committee members and the pharma positions they hold
These are documented cases from public disclosure records. None of the individuals below has been charged with any crime. They are cited because they illustrate a pattern: health committee oversight of the pharmaceutical industry combined with personal investment in that industry, enabled by a disclosure law that imposes no structural barrier to the overlap.
Sen. Richard Burr (R-NC) — HELP Committee + Intelligence Committee Chair
Burr's trades in February 2020 remain the most documented case of potential congressional insider trading in the modern era. As both chairman of the Senate Intelligence Committee and a member of the HELP Committee, he received classified threat assessments and HELP Committee briefings on COVID-19 before the scale of the crisis was publicly known. One day after attending a HELP Committee briefing on February 12, 2020, he sold 33 positions worth between $628,000 and $1.72 million, representing nearly all of his personal retirement holdings. Simultaneously, he gave a private speech describing the pandemic in terms far more alarming than his public statements suggested. The DOJ opened a criminal investigation and obtained a warrant for his phone. The DOJ ultimately closed the investigation without charges. The SEC continued a parallel investigation. No charges were filed under the STOCK Act or any other statute.
Sen. Rand Paul (R-KY) — HELP Committee member
On February 26, 2020, Kelley Paul purchased between $1,001 and $15,000 of Gilead Sciences stock. The purchase was made one day after Gilead's remdesivir began its first clinical trial as a potential COVID-19 treatment. Rand Paul sat on the Senate HELP Committee, which had been receiving coronavirus briefings from government health officials in the preceding weeks. The trade was disclosed to Congress in August 2021, approximately 16 months after it was made. The STOCK Act requires disclosure within 45 days. Paul's office attributed the delay to an oversight. His fine for the late disclosure: $200. Gilead's remdesivir would subsequently become one of the few early-approved treatments for COVID-19, receiving emergency use authorization from the FDA in May 2020. Gilead's stock moved materially on each significant remdesivir development. No investigation was opened.
Rep. Michael Burgess (R-TX) — House Energy and Commerce, Health Subcommittee
Burgess, a physician and longtime member of the House subcommittee that oversees vaccines and FDA drug approvals, held shares in multiple vaccine manufacturers simultaneously with his subcommittee's oversight of those companies. When Pfizer and Moderna executives testified before his subcommittee on COVID vaccine development, Burgess held financial positions in vaccine company stocks. His total exposure across vaccine-related positions reached significant amounts. This represents the direct form of overlap the STOCK Act was intended to address: the legislator questioning a company's executives about a government-regulated product while holding stock in that company. No STOCK Act violation was cited; his holdings were technically disclosed within required deadlines.
Sen. Ashley Moody (R-FL) — Senate HELP Committee
A February 2026 CNN investigation found that Moody, a member of the Senate HELP Committee, had purchased between $100,000 and $250,000 in Eli Lilly stock in March 2025. Eli Lilly had spent millions lobbying Congress in that period. The HELP Committee chair simultaneously released a drug pricing report that relied on Eli Lilly testimony. Moody's office stated she neither initiated nor approved the trades, attributing decisions to an investment partnership. Eli Lilly is the maker of tirzepatide (Mounjaro and Zepbound), whose GLP-1 obesity drugs represent the most valuable new drug franchise of the decade, and whose Medicare reimbursement status is directly subject to decisions made by the Finance and HELP committees Moody serves on.
These cases are not the full picture. A broader analysis found that 97 members of Congress, or their spouses or dependents, traded in companies affected by their committee assignments between 2019 and 2021. Approximately 18% of all members of Congress traded stocks in sectors related to their committee work over the same period. Consumer Watchdog documented 38 senators holding approximately $134 million in pharmaceutical stock who voted on an industry-favorable deal. The most active congressional stock traders include members sitting on the committees that write drug pricing legislation and oversee FDA approvals.
The FDA calendar: how known deadlines create binary risk events
Pharma and biotech investing has a feature with no parallel in any other sector: the PDUFA date. Under the Prescription Drug User Fee Act, the FDA commits to completing standard drug reviews within 10 months and priority reviews within 6 months of a drug application being filed. Once an application is submitted, the PDUFA deadline is public knowledge. Every investor in the market knows that the FDA must approve or reject the drug on or before a specific date. The PDUFA date is a scheduled binary event: the stock will either surge on approval or collapse on rejection.
What is not public before that date is the substance of what the FDA has been communicating with the drug's sponsor, whether the agency has raised additional questions, whether an advisory committee meeting has been called (which often signals uncertainty), and whether FDA reviewers have formed a preliminary view. The briefing documents for an advisory committee meeting are released only 2 to 3 days before the vote, and they contain the FDA's own internal analysis. A favorable FDA reviewer memo virtually assures approval; a skeptical memo typically precedes rejection. Members of Congress who receive FDA leadership briefings on program-level trends, approval rate patterns by therapeutic area, and the agency's evolving standards have a contextual advantage in interpreting these events.
The FDA approved 55 new drugs in 2023 and 50 in 2024. For large pharmaceutical companies, these approvals represent incremental revenue on existing franchises. For small and mid-cap biotechs, a single approval is often the difference between survival and failure. Stocks of small biotechs move 30 to 80 percent on FDA approval decisions, in either direction. Complete Response Letters (CRLs), the FDA's formal rejection mechanism, have sent individual biotech stocks down 50 to 80 percent overnight. Sesen Bio fell more than 80% on a CRL; BioMarin lost over 30% on a rejection for a hemophilia gene therapy. The asymmetry between what committee members know about the FDA's standards and what the market knows is the specific information gap that makes health committee membership uniquely relevant to pharmaceutical investing.
The FDA follows its own advisory committees approximately 78 to 84% of the time in normal periods. In 2025, however, the agency overrode its own expert committees 43% of the time, a striking departure from historical norms. This rate of override itself is information: it tells an informed observer that FDA approvals are less predictable from advisory committee votes than they have been historically. HELP Committee members who receive FDA leadership briefings on agency decision-making patterns have access to this context before it becomes apparent to the broader market through published approval decisions.
What makes a pharma or biotech trade worth examining
Most congressional purchases of pharmaceutical stocks are noise. These are the factors that distinguish a routine holding from a trade that reflects structural information advantage.
Committee assignment matches the company
A HELP or Finance Committee member buying Eli Lilly is categorically different from an Armed Services Committee member buying the same stock. The former writes the drug pricing laws that determine Lilly's Medicare revenue, oversees the FDA that approves its drugs, and receives briefings from the officials implementing both. The committee overlap is structural, not incidental.
Timing relative to PDUFA dates and advisory committee meetings
Trades placed in the weeks before a known FDA decision deadline, or in the period between an advisory committee briefing document release and the vote, carry elevated scrutiny. A member of the HELP Committee purchasing a biotech stock 30 days before its PDUFA date represents a trade that should be evaluated against the member's access to FDA briefings on that therapeutic area's approval environment.
Timing relative to drug pricing legislation
The IRA's drug pricing provisions did not emerge in a single bill vote. They were debated, amended, modeled, and re-debated over months of Finance and HELP Committee markups. Trades made during that legislative process by members of those committees reflect access to draft provisions, CBO modeling of specific company impacts, and internal committee negotiations that were not publicly available until after the bill passed.
Options versus stock purchases
Call options on a biotech stock ahead of a PDUFA date express directional conviction with a specific expiration. This is not how a passive long-term investor holds pharmaceutical exposure. Options purchases by health committee members in companies with near-term FDA decisions represent the highest-signal form of the conflict of interest because they combine committee access with an active, time-specific bet on a government-determined outcome.
Trades involving IRA-affected companies
The 10 drugs in the first Medicare negotiation round were known to be likely candidates well before CMS announced them, to anyone who understood the IRA's selection methodology. Trades in BMS, Merck, AbbVie, J&J, and AstraZeneca by Finance Committee members during the period when the selection process was being finalized represent an ongoing information advantage that the market could not replicate from public sources alone.
Late or amended disclosures
The STOCK Act requires disclosure within 45 days. Late disclosures do not invalidate the trade, but they reduce the ability to correlate timing with known government information events. Rand Paul's 16-month delay in disclosing his wife's Gilead purchase is an extreme example. A trade disclosed on time still cannot be proven to reflect insider information; a trade disclosed many months late cannot even be properly evaluated against the legislative calendar. The pattern of late filing in health sectors is worth tracking separately.
Frequently asked questions
Yes, under current law. The STOCK Act of 2012 prohibits trading on material non-public information but does not ban stock ownership or trading in sectors under direct committee oversight. A senator who writes drug pricing legislation on the Finance Committee can legally hold Merck, BMS, or AbbVie stock. A senator who oversees the FDA on the HELP Committee can legally hold Eli Lilly, Biogen, or Pfizer. The only requirements are disclosure within 45 days and that no specific classified document can be proven to have directly motivated the trade. Multiple congressional stock ban bills have been introduced. None has passed.
The Finance Committee wrote the IRA's drug pricing provisions and has ongoing oversight of CMS implementation. The selection formula for which drugs enter negotiation is based on Medicare spending thresholds and the absence of generic or biosimilar competition. Finance Committee members understood this methodology during bill drafting, before CMS formalized and published the selection criteria publicly. Any member who understood the formula could run the same analysis CMS would run and identify which drugs were most likely to be selected. The first 10 drugs announced in August 2023 included the highest-spending Part D drugs without generic competition: exactly what the formula predicted. The companies with the most exposure (BMS, Merck, AbbVie, J&J) were identifiable to informed insiders well before August 29, 2023.
For large-cap pharmaceutical companies, FDA approvals typically move stocks 3 to 15 percent, reflecting a new drug's incremental contribution to an existing diversified revenue base. For small and mid-cap biotechs where the drug being reviewed represents the company's primary or only pipeline asset, the moves are far more extreme. Biogen surged 38 to 64 percent in a single session when the FDA approved Aduhelm in June 2021. Rejections via Complete Response Letters produce comparable collapses in the other direction: Sesen Bio fell more than 80%, Replimune fell 76% to under $3 per share, BioMarin lost over 30% on a single CRL. These single-day moves are larger than what most stocks experience over years of normal trading, which is why the information asymmetry around FDA decisions is among the most valuable in any market.
Bristol-Myers Squibb faces the largest absolute dollar impact from the IRA, driven by Eliquis's $16.4 billion annual Medicare Part D spending. Merck faces the deepest percentage cut, with Januvia's negotiated price representing a 79% discount from list. AbbVie's Imbruvica and the transition of Humira to biosimilar competition have made it among the most government-exposed large-cap pharma companies. In a different category, Eli Lilly and Novo Nordisk face the most consequential pending government decision: whether CMS will broadly cover GLP-1 obesity drugs under Medicare Part D. That coverage decision, currently under deliberation, would determine whether the two companies' obesity franchises gain a multi-billion-dollar new customer base entirely through government payer expansion. The Finance and HELP committees will have advance knowledge of the direction of that decision before it is publicly announced.
Congressional trade disclosures are public records filed as Periodic Transaction Reports under the STOCK Act, available on the House Clerk and Senate Secretary portals. A raw disclosure tells you a member bought Eli Lilly in a $50,001 to $100,000 bracket. It does not tell you whether that member sits on the Finance or HELP Committee, whether the disclosure was filed on time, or whether the timing aligns with a drug pricing markup, a known PDUFA date, or an advisory committee vote. Kapitol.ai curates these disclosures with committee context and insider significance scoring, so you can see which trades carry structural information advantage. Understanding how to read a congressional stock disclosure is a prerequisite to evaluating them correctly: the amount brackets, late-filing patterns, and owner codes each carry meaning that raw data alone does not communicate.
The senator who wrote the drug pricing law and the investor holding pharma are sometimes the same person. We track both.
Every trade we publish carries committee context, legislative timing, and a significance score. Not a raw database. A curated intelligence feed.